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Background: Vitamin D deficiency is associated with cardiovascular (CV) risk in multiple populations, including
those with chronic kidney disease (CKD). The active form of the hormone (1,25 OH2D3) binds to receptors in
multiple organs. CKD patients are deficient in both 25 Vitamin D and 1,25 OH2D3. Clinical trial data demonstrating
the benefits of vitamin D formulations are limited, and fail to show significant benefits on CV outcomes, and have
compared different compounds, in various populations, and focused on a variety of outcomes. A understanding of
the mechanism by which different vitamin D compounds confer CV protection in CKD is important for the design
of future studies.
Methods/Design: This 3 arm randomized prospective double-blinded placebo-controlled study examining the
impact of calcitriol (1,25 OH2D3) and 25-hydroxyvitamin D3 supplementation compared to placebo on vascular
stiffness, as measured by pulse wave velocity (PWV). Patients are enrolled from 2 tertiary care institutions if they
meet inclusion criteria (stable estimated glomerular filtration rate (eGFR) between 15-45ml/min, <±5ml/min
change in previous 6 months), on stable doses of renin-angiotensin aldosterone system blockade. For those
already receiving vitamin D therapies, a 3 month washout period before randomization is mandatory.
Treatment duration is 6 months; medications are given thrice weekly in fixed doses. The primary outcome
measure is Vascular stiffness, measured non-invasively by pulse wave velocity (PWV). Other measurements include BP,
kidney function and serial blood levels of biomarkers. The primary analysis will compare any vitamin D therapy versus
placebo for the primary outcome defined as the change of PWV from baseline to 6 months. Analysis of covariance will
be used to detect differences between vitamin D preparations in the magnitude of reduction in PWV.
Discussion: This study is novel in that we are using a robust study design in CKD patients (not on dialysis) comparing
placebo to different forms of vitamin D supplementation in fixed doses, irrespective of baseline values. We hope to
demonstrate the biological mechanistic effect of vitamin D supplementation on vascular function in order for this
information to be used in designing larger randomized controlled trials.
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Cardiovascular (CV) disease in chronic kidney disease
(CKD) is highly prevalent and is associated with a sig-
nificant increase in morbidity and mortality [1]. Vascular
dysfunction and CV disease are caused by a combination
of atherosclerotic processes (mediated by dyslipidemia
and smoking) and arteriosclerotic processes such as
aging, diabetes, vitamin D deficiencies, hyperphosphate-
mia and hyperparathyroidism (HPTH). The latter is as-
sociated with vascular stiffness, loss of collagen and
elastin fibers [2]. CKD patients have both ‘conventional’
and non-conventional risk factors for CV disease; and
high prevalence of left ventricular hypertrophy (LVH)
has been noted. To date, conventional CV disease risk
reduction agents and strategies (renal angiotensin aldos-
terone system (RAAS) antagonists, anti-platelet agents,
lipid lowering agents) have either not been systematically
evaluated in all CKD populations, or do not appear to
mitigate CV disease risk to the extent that they are ef-
fective in non-CKD populations. Furthermore, strategies
to address non-conventional risk factors (anemia, hyper-
phosphatemia) on outcomes have either shown no impact,
harm, conflicting results, or have not been evaluated in a
rigorous randomized control trial with clinically meaning-
ful endpoints [3].
Vitamin D deficiency, (25 OHD3) is common in both
CKD and general populations. It has been associated in
animal and human studies with hypertension (HTN),
diabetes, obesity and inflammation, and proteinuria. It is
these associations that has led some to regard it as an
important CV disease risk factor [4-6]. CKD patients
have low levels of 25-hydroxyvitamin D (25 vitamin D),
but also lack the physiological capacity to hydroxylate 25
vitamin D into its active form 1,25-dihydroxyvitamin D
(1,25 vitamin D), which binds to the vitamin D receptors
(VDR) found in blood vessels, the heart, muscles and
kidneys. Animal studies describe the impact of VDR
activators on inflammation in both kidneys and hearts.
In addition, LVH has been noted, and reversed with sup-
plementation [7]. [ Human studies have demonstrated
reduction in proteinuria [8,9] and some impact on
changes in eGFR. These are small studies of limited dur-
ation. Thadhani et al. have found that treatment with
paricalcitol (a VDR activator) in CKD patients reduces
parathyroid hormone (PTH) levels within 4 weeks of
commencing treatment versus a placebo [10], however,
did not impact the primary outcome ( LV mass), but did
reduce the number of CV disease-related hospitaliza-
tions over the trial period. Large cohort studies have also
demonstrated reductions in 1,25 vitamin D and 25 vita-
min D in CKD populations in association with rises in
serum PTH values [11], at eGFR levels commencing
around 50mL/min/1.73m2. While CKD patients may be
able to hydroxylate 25 vitamin D outside the kidney, therelative effectiveness of these mechanisms have not been
studied [2]. The prevailing theory is that the combined
25 OHD3 and 1,25 OH2D3 deficiencies seen in CKD do
impact outcomes.
The association between 25 vitamin D deficiency and
CV disease has been demonstrated in numerous popula-
tions [5,12]. The active hormone modulates a variety of
processes directly associated with arteriosclerotic changes
via its interactions with specific biomarkers and inflamma-
tory processes [13-17]. As a recent Cochrane review as-
serts, no prospective randomized controlled study to date
have demonstrated the effect of vitamin D supplementa-
tion to reduce CV disease events [18]. Given the multiple
reported effects of vitamin D on PTH, phosphate (PO4),
blood pressure (BP), inflammation, insulin sensitivity and
other factors, it is imperative to demonstrate a biological
impact of vitamin D on vascular function, which could be
directly in the causal pathway for CV disease [11,15,19,20].
There are non invasive methods of studying vascular
stiffness, the most used of which is Pulse wave velocity
(PWV) using standardized validated equipment ( aSphyg-
moCor). This technique utilizes applanation tonometry to
measure the velocity of the pulse wave between two points
on the arterial tree [21]. Increased vascular stiffness ( higher
PWV values) is associated with LVH, poor CV disease out-
comes, and death in dialysis populations [22,23]. The re-
producibility and validity of this measurement has been
demonstrated both in the general population and in those
with kidney failure [22,24,25]. Utilizing PWV measure-
ments, we will attempt to demonstrate changes in vascular
stiffness with various forms of vitamin D supplementation
in a non dialysis CKD population.Methods/Design
Overarching objectives
The overarching objective of this study is to describe the
impact of currently used formulations of vitamin D (25
vitamin D3 and calcitriol) on vascular stiffness in patients
with CKD, eGFR levels between 15 and 45 mL/min/
1.73m2. We hypothesize that supplementation with vita-
min D analogues will result in greater reductions in PWV
measurements than placebo when compared to baseline
measurements.Study cohort
Subjects will be drawn from a cohort of CKD patients
treated according to best practices at university based
tertiary care centers in Vancouver. Following written in-
formed consent, subjects who fulfill eligibility criteria at
screening (Table 1) will be randomized (1:1:1) to receive
treatment of 25 vitamin D3 at 5000IU three times a
week, 1,25 vitamin D (calcitriol) at 0.5ug three times a
week, or placebo.
Table 1 Inclusion/exclusion criteria
Inclusion criteria Exclusion criteria
- Signed informed consent - Refused informed consent
- eGFR between 15-45 ml/min - Change of >5ml/min eGFR over
the past 6 months
- Change of <5ml/min in eGFR
over the past 6 months
- Planned transplant within 6
months
- Treated with maximal
conventional CV disease risk
reduction protocolized
medications (ACEi or ARB)
- Likely to commence renal
replacement therapy within 6
months after enrolment
- Currently receiving vitamin D
therapies, but agreeing to a
washout period of 3 months
- Terminal malignancies
- Active infections
- Active inflammatory diseases (SLE,
vasculitis)
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The study is funded from a peer reviewed grant from
Kidney foundation of Canada (KFoC) in collaboration
with Pfizer. The study addresses specific interests of the
KFoC, focusing on Canadians with CKD at risk for
CVD, and identifying potential benefits of adjunct ther-
apy in a complex condition.
Statement of purpose
This physiological study will describe the impact of vita-
min D therapies on a physiological measure related to
CVD in CKD: vascular stiffness. Describing this mechan-
ism would enhance the viability of testing longer term
outcomes using these interventions.
Primary questions:
1. Does treatment with vitamin D analogues for a
period of 6 months reduce PWV in CKD patients as
compared to placebo?
Secondary questions:
1. Is there a difference between 1,25 vitamin D and 25
vitamin D formulations in the magnitude of
reduction in PWV?
2. Does 6 month provision of 1,25 or 25 vitamin D
lead to demonstrable reductions in BP (without
changes in antihypertensive medication), or
proteinuria (without change in ACEi/ARB therapy)
relative to placebo?
3. What is the impact of 1,25 vitamin D and 25
vitamin D on blood levels of FGF-23, serum PTH,
PO4 Ca, and CRP in this population? Is there a
relationship between changes in vascular stiffness
and changes in these biochemical/hormonal
parameters?Rationale for the study
There is increasing evidence that vitamin D acting on
multiple aspects of the physiological processes involved
in the pathogenesis of CVD may be an important thera-
peutic strategy in CKD. The intellectual appeal of study-
ing vitamin D supplementation in CKD has led to a
number of proposals for studies of CV outcome in CKD,
and some randomized control trials [3,10,26,27]. While
these studies have shown promising signals (reduction in
proteinuria and reduction in CV hospitalization and
events), no studies have addressed the mechanism of
how vitamin D supplementation might impact these out-
comes in humans, other than via reduction in LV mass
(which was not shown). While both 1,25 vitamin D and 25
vitamin D formulations have been used in clinical studies
to date, controversy continues as to the form of vitamin D
best used in clinical practice to supplement deficiencies
[16,28,29].
Recent meta-analyses and systematic reviews [15,17,
26,30-32] have described epidemiological associations
with 25 vitamin D deficiencies and outcomes, and supple-
mentation as impacting intermediate outcomes (protein-
uria), but not mortality or time to end stage kidney failure.
Quantification of the impact of vitamin D on vascular
stiffness will permit estimates of effect size and stimulate
further research into combining medication strategies.
Interventions
We will prescribe fixed does of 5000IU 25 vitamin D and
0.5μg of 1,25 vitamin D, three times a week, (compatible
with doses given in other studies, and at intervals used in
many clinical practices) in order to maximally stimulate
the circadian impact of the vitamin D therapy. A 6 month
treatment period is chosen to ensure “biologically mean-
ingful exposure” which should permit measurable changes
in blood levels and vascular compliance, as well as miti-
gate the effects of sun exposure. Medications are supplied
in oral suspension with identical look and taste (in almond
oil), so that patients and providers are blinded.
Duration of the study
Each patient will be followed for a period of 6 months
post-randomization. Patients on existing vitamin D supple-
mentation will have been followed for 9 months due to the
additional 3 months of washout prior to randomization.
Study design
This will be a 3 arm prospective randomized double blind
placebo controlled study of 128 stable CKD subjects
examining the impact of vitamin D supplementation (1,25
vitamin D or 25 vitamin D formulations) compared to pla-
cebo on arterial stiffness and other parameters of vascular
health. The study plan shown in Figure 1 will combine
physiological experiments in a well characterized cohort
1,25VD (0.50ug * 3 per week)




Washout (3 months) 6 months
PWV (-3 mo) PWV (0 mo) PWV (6 mo)
Treatment
Arm
Figure 1 The study plan depicts the timeline for the completion of the study. Screening/recruitment includes the 3 month washout period.
Vitamin D doses will be administered for 6 months allowing for the inclusion criteria. PWV will be measured at baseline (-3 months), post
washout period (0 months) and post treatment (6 months) for both treatment arms and their respective placebos.
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methods to test and explore additional related hypotheses.
Sample size considerations
The study is powered to demonstrate differences in
primary outcome between individual study subjects; the
calculated sample size will be adequate to detect a clinic-
ally important effect of vitamin D on PWV (reduction of
1m/sec). The mean difference of 1m/s is clinically mean-
ingful in that it has been demonstrated to confer a 34%
increased risk of CV mortality in a cohort of CKD stage
5 patients on dialysis [33,34]. A sample size of 105 (35
placebo arm and 70 treatment arm) without attrition will
provide 85% power to demonstrate the mean PWV
difference of 1m/s between arms, with 0.05 target alpha
for a two sided test. Thus, recruitment and enrolment of
128 subjects will allow for ~15% attrition.
Trial management
To ensure safety and data integrity, the single research of-
fice centrally located is responsible for the conduct at two
sites within the city, both University teaching hospitals.
The study will be overseen by independent Data Safety
and Monitoring Board (DSMB) and also will review sub-
ject lab results and concomitant medications on a monthly
basis. The DSMB will screen for the adverse events, in-
cluding the possibility of hypervitaminosis, hypercalcaemia
and hyperphosphatemia. In addition, random audits will
be performed to assess data quality.
Variables measured
PWV measurements, clinical and biological samples will
be obtained at pre-washout, baseline, and post treatment
(3 time points). Blood and urine samples will be obtained
at each of the 3 time points to test for serum PTH, 1,25
vitamin D, 25 vitamin D, fibroblast growth factor-23
(FGF-23), PO4, calcium (Ca), C-reactive protein (CRP),
urinalysis and random urine albumin-to-creatinine ra-
tio (UACR). All samples will be run in an accreditedlaboratory using validated assays. BP will be done in
duplicate and PWV will be done in triplicate at each
visit using standardized BP cuffs and SphygmoCor, re-
spectively [35]. Clinical and medication histories as well
as rationale for specific biomarkers are listed in Additional
file 1.
Statistical analysis
The primary analysis will compare vitamin D (25 vitamin
and 1,25 vitamin D) therapies versus placebo for the pri-
mary outcome defined as the change of PWV from base-
line to 6 months by covariance analysis (ANCOVA);
where the 6 month measurement of PWV will be the
dependent variable, allocated treatment the independ-
ent variable, and baseline PWV the baseline covariate
[29,36,37]. Analyses will be considered statistically sig-
nificant if the p-value is <0.05 for allocated treatment.
In case of violation of ANCOVA assumptions we will
use a mixed model approach.
Strengths and weaknesses
It is conceivable that the therapies as administered may
not have an impact on our chosen outcomes of interest:
vascular stiffness, BP or proteinuria (primary or second-
ary). The 6 month time period may not be sufficient
exposure to demonstrate the effect of the vitamin D treat-
ment, or the expected difference in PWV changes/re-
ductions between the groups is different and thus the
study may be underpowered. However, given that this
study uniquely examines non dialysis advance stage CKD
patients, using fixed dose drug administration schedules,
physiological measurements and biochemical measure-
ments serially over time, the study will add to the growing
body of literature regarding the use of vitamin D supple-
mentation in CKD population. If positive, it will inform
future larger studies looking at additional measures such
as LV mass, or function over time in relation to PWV, and
will add to our understanding of the physiology of vascular
changes in CKD. Given the current state of knowledge,
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that fail to consistently demonstrate a benefit to Vitamin
D supplementation, there are no ethical issues conducting
a placebo-controlled trial.
Discussion
There is an accumulating body of evidence that vitamin D
acting on multiple aspects of physiological processes in-
volved in the pathogenesis of CVD and thus may be an
important therapeutic strategy in CKD. Studies conducted
to date have failed to demonstrate significant impact of
hormone supplementation on outcomes. Cholecalciferol
has been studied in 60 patients on hemodialysis, who were
known to be 25 OHD3 deficient and did not show any
change in PWV [38]. Other studies conducted in both
dialysis and non dialysis CKD patients, also included were
those with demonstrable deficiencies for limited time
periods (8 weeks) showed changes in serum levels of 25
and 1, 25 Vitamin D levels [39-42]. Although more pro-
nounced in non dialysis patients, other outcomes were not
measured. Another study demonstrated that 25 OHD3
supplementation in post menopausal women did not re-
duce CV risk, when studied in a randomized control trial
[43]. These studies were all relatively short term and fo-
cused on different questions than the ones we are attempt-
ing to answer in this study. We believe that attempting to
establish a biological mechanistic effect of vitamin D sup-
plementation on vascular function is necessary before fur-
ther larger randomized controlled trials are undertaken.
Given the purported differential ability of CKD patients to
achieve appropriate concentrations of the active com-
pound, the question of which supplementation is more ap-
propriate, 25 vitamin D or 1,25 vitamin D in CKD remains
controversial. The relationship of serum levels to disease,
type of therapeutic supplementation (fixed dose or based
on targeting serum levels) is unknown in CKD popula-
tions. Moreover, in various nephrology studies, attempts
at targeting deficiencies or excesses of measured serum
values in CKD patients in large randomized control trials
has not met with success [44-47]. Thus, we have devel-
oped and designed a robust randomized control trial to
attempt to address deficiencies in the literature, and to
better understand mechanisms and complex biological
interactions in this patient group.
We expect to find vitamin D to have an impact on
vascular stiffness and BP irrespective of serum vitamin D
levels. The impact will be greatest on those with highest
PWV. The data generated herein will permit the develop-
ment of a set of phenotypes using clinical and biomarker
data. Such that characterization of patients according to
PWV, BP, FGF-23 and vitamin D levels will be possible,
and results of treatment strategies will be examined within
the phenotype category. This information will be signifi-
cant for future enrolment in clinical trials. The biomarkeranalyses will aid in explaining any dissociation found
between BP and vascular stiffness.
Before large randomized trials can be developed, these
unanswered questions regarding the mechanism of disease
require resolution to ensure pertinent study design. This is
an ‘intermediate’ study which fully examines the physio-
logical consequences of different vitamin D therapies in
CKD populations. The findings will be used to understand
physiological mechanisms, generate further hypotheses for
testing, and ultimately contribute to evidence base studies
which will inform clinical practice.
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